PF-05089771
- Generic Name
- PF-05089771
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H12Cl2FN5O3S2
- CAS Number
- 1235403-62-9
- Unique Ingredient Identifier
- 25U4N985O2
- Background
PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).
- Associated Conditions
- -
- Associated Therapies
- -
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 36
- Registration Number
- NCT05935280
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01854996
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
Safety And Tolerability Study Of BID Titration Scheme With PF-05089771
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT01772264
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT01769274
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study Comparing PF-05089771 TS Capsule To PF-05089771 TS Oral Dispersion In The Fasted State
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01690351
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Study Comparing PF-05089771 TS Tablet to PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01563497
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT01529671
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
Efficacy Of PF-05089771 In Treating Postoperative Dental Pain
- Conditions
- Interventions
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 235
- Registration Number
- NCT01529346
- Locations
- 🇺🇸
Central Texas Oral Surgery Associates, Austin, Texas, United States
🇺🇸Premier Research Group Limited, Austin, Texas, United States
🇺🇸PPD Development, LP, Austin, Texas, United States
The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2011-10-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT01365637
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Single Dose Escalation Study In Healthy Volunteers To Determine The Pharmacokinetics, Safety And Tolerability Of PF-05089771 In Healthy Volunteers
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT01259882
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.